Completed
PHASE3
INTERVENTIONAL
NCT05822830
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Semaglutide
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change From Baseline in Body Weight
TimeFrame:
Baseline, Week 72
Description:
Percent change from baseline in body weight was reported. Least Squares (LS) mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.
Trial Information
NCT ID
NCT05822830
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025